Novartis, the Swiss drugmaker, reported second-quarter results that were steady rather than spectacular, and reaffirmed a full-year outlook that is more cautious than the sales line suggests. The figures here are from Novartis's own results release.

The quarter

Net sales were $14.408 billion, up 3% in US dollars but only 1% in constant currencies. Core operating income was $5.940 billion, flat year on year. Core earnings per share were $2.41, unchanged in dollars and down 1% in constant currencies.

The gap between the dollar and constant-currency figures is the first thing to read. Constant-currency growth strips out exchange-rate movements to show the underlying business, and on that measure sales rose 1% and earnings slipped slightly. The larger dollar growth reflects currency translation, not stronger demand. For a company that sells globally and reports in dollars, the honest read of the operating performance is the constant-currency one, and it says: roughly flat.

The guidance is the story

The more informative number is the outlook, which Novartis reaffirmed rather than raised.

For full-year 2026, the company expects net sales to grow at a low single-digit rate and core operating income to decline at a low single-digit rate, in constant currencies. That is an unusual shape: revenue edging up while profit edges down.

A guidance in which profit falls as sales rise tells you margins are under pressure. For a large pharmaceutical company, that pattern usually reflects some combination of heavier spending on research and on launching newer products, pricing pressure in mature markets, and the cost of defending or replacing revenue as older drugs face competition. Novartis did not frame the quarter as a disappointment, and reaffirming guidance signals the year is tracking to plan; but the plan itself has profit going backwards, and that is worth more attention than a headline dollar-sales figure flattered by currency.

Note on the "beat" framing

Wire coverage described the quarter as topping estimates. That may well be accurate against analysts' consensus, but a "beat" is a comparison to expectations, and we could not independently verify the consensus figures from a reachable source for this piece. So we report what Novartis actually delivered, sales up 1% in constant currency, flat core operating income, guidance reaffirmed, rather than characterize it against a benchmark we have not confirmed. Steady results can beat a low bar or miss a high one; the underlying numbers are the same either way.

Capital returns, and a bigger balance sheet

Novartis has kept returning cash. In the first half of 2026 it bought back 18.2 million shares for $2.8 billion and paid $9.1 billion in dividends.

One balance-sheet number stands out. Net debt rose to $39.4 billion at June 30, from $21.9 billion at the end of 2025, an increase of about $17.5 billion in six months. A jump of that size in half a year is not generated by ordinary operations; it reflects capital deployment, dividends and buybacks alongside acquisitions, against the cash the business threw off. Novartis has been active in expanding its oncology portfolio through dealmaking, and a rising net-debt figure is the financing counterpart of that strategy. It is not alarming for a company of this cash generation, but it is a real change in the capital structure over a short window, and it is the kind of line an investor should not skip past.

What it adds up to

Novartis is a stable, cash-generative business that is, on the evidence of this quarter and its own guidance, running close to flat at the operating level while it invests through a portfolio transition. The verifiable facts: Q2 net sales $14.408bn (+1% constant currency), core operating income $5.940bn (flat), core EPS $2.41; full-year guidance reaffirmed at low-single-digit sales growth and a low-single-digit core operating income decline; $2.8bn of buybacks and $9.1bn of dividends in the half; net debt up to $39.4bn.

The reaffirmed guidance is the takeaway. A year in which a major drugmaker expects to sell a little more and earn a little less is a year of transition, and the market's question for Novartis is whether the newer products it is spending to build carry the profit line back up once that transition is further along.